This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $268,345 to the Sanford Burnham Prebys Medical Discovery Institute to develop a novel immunotherapy to treat pancreatic cancer. The goal is to target the PSGL-1/VISTA axis as a means to enhance T cell responses and overcome resistance to current immune checkpoint blockade therapy. The research will 1) investigate the role of the PSGL-1/VISTA axis in regulating T cell activity, 2) determine the impact of PSGL-1 blockade on T cell infiltration and response in pancreatic cancer tumors, and 3) evaluate biomarkers that predict sensitivity to PSGL-1 targeting in pancreatic cancer patients. This award runs from March 2025 through February 2027.
Generated 3/25/25, 3:32 AM